logo
Plus   Neg
Share
Email

Takeda Grants License To Neurocrine Biosciences For Seven Pipeline Programs

Neurocrine Biosciences, Inc. (NBIX) and Takeda Pharmaceutical Company Limited (TAK) have entered a strategic collaboration to develop and commercialize compounds in Takeda's early-to-mid-stage psychiatry pipeline. Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.

Takeda will receive a total of $120 million in upfront cash. Takeda will also be entitled to development milestones of up to $495 million, commercial milestones of up to $1.4 billion and up to double-digit royalties on net sales.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Humana Inc. (HUM) reported second quarter adjusted earnings per share of $12.56 compared to $6.05, previous year. On average, 22 analysts polled by Thomson Reuters expected the company to report profit per share of $10.27, for the quarter. Analysts' estimates typically exclude special items. Second... H-E-B has issued an all-store recall for Blue Cheese Salmon Burgers citing the presence of an undeclared allergen, the U.S. Food and Drug Administration announced. The products contain wheat, a known allergen, which is not declared on the product label. Consumers with allergy or severe sensitivity to wheat may get serious or life-threatening allergic reaction if they consume these products. The U.S. Securities and Exchange Commission is investigating the circumstances around Eastman Kodak Co.'s (KODK) announcement of a $765 million government loan to make ingredients for Covid-19 drugs, the Wall Street Journal reported citing people familiar with the matter.
Follow RTT